本帖最后由 老马 于 2012-1-13 21:20 编辑 0 n6 G* i9 A# n- N" j( o
/ k3 p" h) K( n2 Z* k爱必妥和阿瓦斯丁的比较' v1 _+ P$ N) i0 H. ^. d. }- _
+ |, y k# Y- I! P# Z6 j
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
; s! S! R9 \4 X m$ j
' b' \' ~4 W6 t) N: Y1 n# {# u2 w
0 O, h9 n* I2 C! K7 Uhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
. Q8 g y8 d. x" q9 Q==================================================
) C9 l% ]* s9 _# Z F3 X( U: IOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
0 Q- l$ r3 Z9 K0 C1 ~$ ], nPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
8 V8 h! ~9 r8 c, \5 FResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
) F" u1 q; K# I8 O. r' G
|